Bradley Canino
Stock Analyst at Stifel
(2.17)
# 1,479
Out of 4,479 analysts
70
Total ratings
39.34%
Success rate
-4.2%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $42 | $20.66 | +103.29% | 4 | Jun 26, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $32 → $10 | $3.57 | +180.11% | 17 | Jun 18, 2024 | |
| MRUS Merus | Maintains: Buy | $90 → $99 | $53.09 | +86.48% | 7 | Jun 17, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $8 → $14 | $7.54 | +85.68% | 2 | Jun 3, 2024 | |
| CELC Celcuity | Maintains: Buy | $40 | $16.19 | +147.07% | 2 | May 16, 2024 | |
| CCCC C4 Therapeutics | Maintains: Buy | $13 → $14 | $4.52 | +209.73% | 4 | May 9, 2024 | |
| ARVN Arvinas | Maintains: Buy | $72 → $68 | $24.85 | +173.64% | 5 | May 8, 2024 | |
| CGEM Cullinan Oncology | Initiates: Buy | $40 | $16.31 | +145.25% | 1 | May 1, 2024 | |
| BPMC Blueprint Medicines | Maintains: Buy | $120 → $130 | $110.36 | +17.80% | 5 | Apr 26, 2024 | |
| AFMD Affimed | Maintains: Hold | $1 → $5 | $5.16 | -3.01% | 4 | Apr 1, 2024 | |
| ALXO ALX Oncology Holdings | Downgrades: Hold | $10 → $14 | $5.72 | +144.76% | 4 | Mar 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $35 → $55 | $30.22 | +82.00% | 4 | Feb 23, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $25 → $30 | $6.47 | +363.68% | 3 | Feb 22, 2024 | |
| NUVL Nuvalent | Reiterates: Buy | n/a | $73.00 | - | 2 | Oct 4, 2023 | |
| BDTX Black Diamond Therapeutics | Upgrades: Buy | $2 → $10 | $4.21 | +137.53% | 4 | Jun 30, 2023 | |
| KURA Kura Oncology | Maintains: Buy | $24 → $25 | $20.58 | +21.48% | 2 | Jun 12, 2023 |
Syndax Pharmaceuticals
Jun 26, 2024
Maintains: Buy
Price Target: $40 → $42
Current: $20.66
Upside: +103.29%
Zentalis Pharmaceuticals
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.57
Upside: +180.11%
Merus
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $53.09
Upside: +86.48%
Summit Therapeutics
Jun 3, 2024
Maintains: Buy
Price Target: $8 → $14
Current: $7.54
Upside: +85.68%
Celcuity
May 16, 2024
Maintains: Buy
Price Target: $40
Current: $16.19
Upside: +147.07%
C4 Therapeutics
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $4.52
Upside: +209.73%
Arvinas
May 8, 2024
Maintains: Buy
Price Target: $72 → $68
Current: $24.85
Upside: +173.64%
Cullinan Oncology
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $16.31
Upside: +145.25%
Blueprint Medicines
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $110.36
Upside: +17.80%
Affimed
Apr 1, 2024
Maintains: Hold
Price Target: $1 → $5
Current: $5.16
Upside: -3.01%
ALX Oncology Holdings
Mar 8, 2024
Downgrades: Hold
Price Target: $10 → $14
Current: $5.72
Upside: +144.76%
Kymera Therapeutics
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $30.22
Upside: +82.00%
Relay Therapeutics
Feb 22, 2024
Maintains: Buy
Price Target: $25 → $30
Current: $6.47
Upside: +363.68%
Nuvalent
Oct 4, 2023
Reiterates: Buy
Price Target: n/a
Current: $73.00
Upside: -
Black Diamond Therapeutics
Jun 30, 2023
Upgrades: Buy
Price Target: $2 → $10
Current: $4.21
Upside: +137.53%
Kura Oncology
Jun 12, 2023
Maintains: Buy
Price Target: $24 → $25
Current: $20.58
Upside: +21.48%